CNBC launches the iQ 100 Index of large-cap companies that derive substantial revenue from their intellectual property.
The FDA and Congress enabled Mylan to secure a monopoly on EpiPens and then jack up the prices, says this intellectual-property expert.
David Martin, M-CAM Founder, discusses the EpiPen pricing saga and his view that the patent office gave Mylan an unjustified monopoly on the drug.
Take an in-depth look at the world of modern medicine - examining the treatments, companies and people making a difference in the way we treat illness and injuries today, and laying the foundation for the medical treatments of tomorrow.
A data-driven index of 100 large-cap companies best using technology to invest in and profit from new business opportunities.
Financial advisors stress that now is the time for investors to get serious about year-end financial planning checkup.